ResMed Inc is a global leader in digital health and cloud-connected devices that serve individuals with sleep apnea, chronic obstructive pulmonary disease (COPD), and other chronic respiratory conditions. The company specializes in creating innovative solutions that improve the quality of life for patients through advanced technology, including ventilators, sleep therapy devices, and patient monitoring systems. By leveraging data analytics and machine learning, ResMed enhances patient engagement and treatment adherence, thereby promoting better health outcomes. The company's commitment to research and development allows it to continuously advance its portfolio, making a significant impact on the healthcare landscape. Read More
Medical device company ResMed (NYSE:RMD) reported Q1 CY2026 results exceeding the market’s revenue expectations, with sales up 10.8% year on year to $1.43 bi...
A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion o...
Medical device company ResMed (NYSE:RMD) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up 10.8% year on year to $1.43 billion...
SAN DIEGO, April 30, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced that Brett Sandercock, Chief Financial Officer, plans to retire effective May 4, 2026. After conducting a comprehensive search, Aaron Bloomer has been appointed as his successor.
Medical device company ResMed (NYSE:RMD) will be announcing earnings results this Thursday afternoon. Here’s what to look for. ResMed beat analysts’ revenue ...
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f...
ResMed Inc. offers a sustainable dividend with a 10-year growth history, backed by strong profitability, a low payout ratio, and a rock-solid balance sheet for durable passive income.
SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2026 on Thursday, April 30, 2026, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking a...
What Happened? Shares of medical device company ResMed (NYSE:RMD) fell 2.6% in the afternoon session after its Chairman and CEO, Michael J. Farrell, sold sha...
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have se...
